Terumo Blood and Cell Technologies Appoints Gene Stellon to Lead Innovation and Development
Lakewood, Colorado, US, April 5, 2022 – Terumo Blood and Cell Technologies, a medical technology company recently appointed Gene Stellon as Senior Vice President, Innovation and Development. He will serve on the Executive Management Committee.
Gene joins Terumo Blood and Cell Technologies from Medtronic, where he served as the Vice President, Research and Development Surgical Energy and Safety and Gynecological Health (GYN) within Surgical Innovations. Throughout his career, he has held successive leadership roles in Research and Development, including at US Surgical as a manufacturing engineer supporting access and ligation devices along with surgical staplers. Gene served in the U.S. Air Force and the Connecticut, Air National Guard, retiring in 2015.
Terumo Blood and Cell Technologies specializes in products that collect and process blood and cells. Innovation and development are at the forefront of the company’s efforts. The company spends three times the industry average funding technology advances – making this Innovation and Development role critical. Such investment has been instrumental in funding new innovations including those for plasma collections and the cell and gene therapy industry.
Gene will lead the Innovation and Development department for Terumo Blood and Cell Technologies with the focus on building a strong pipeline of future innovations. He will focus on effectively launching projects in development across our portfolio into emerging growth markets that will ultimately help us touch more patients’ lives.
"Gene brings a deep operating foundation formed in the military and private sectors,” said Antoinette Gawin, President and Chief Executive Officer, Terumo Blood and Cell Technologies. “This will speed up our cycle time from innovation to product launch and patient impact. His experience in different development areas will help connect the technology and tools of tomorrow with our platforms today.”
Gene said: “Terumo Blood and Cell Technologies has established itself as one of the foremost medical technology companies in blood and cell collections and processing. Its technology has already touched so many patients. Still, there is enormous opportunity to leverage technology and our global talent to being exciting new therapies to market, allowing us to serve more unmet needs and touch more patients.”
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.
Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers, plasma centers and private medical practices. Our customers are based in over 130 countries across the globe. We have more than 750 granted patents, with more than 150 additionally pending.
We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.